Article | Published:

TACE (ADAM17) inhibits Schwann cell myelination

Nature Neuroscience volume 14, pages 857865 (2011) | Download Citation

Abstract

Tumor necrosis factor-α–converting enzyme (TACE; also known as ADAM17) is a proteolytic sheddase that is responsible for the cleavage of several membrane-bound molecules. We report that TACE cleaves neuregulin-1 (NRG1) type III in the epidermal growth factor domain, probably inactivating it (as assessed by deficient activation of the phosphatidylinositol-3-OH kinase pathway), and thereby negatively regulating peripheral nervous system (PNS) myelination. Lentivirus-mediated knockdown of TACE in vitro in dorsal root ganglia neurons accelerates the onset of myelination and results in hypermyelination. In agreement, motor neurons of conditional knockout mice lacking TACE specifically in these cells are significantly hypermyelinated, and small-caliber fibers are aberrantly myelinated. Further, reduced TACE activity rescues hypomyelination in NRG1 type III haploinsufficient mice in vivo. We also show that the inhibitory effect of TACE is neuron-autonomous, as Schwann cells lacking TACE elaborate myelin of normal thickness. Thus, TACE is a modulator of NRG1 type III activity and is a negative regulator of myelination in the PNS.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.

References

  1. 1.

    et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 47, 681–694 (2005).

  2. 2.

    et al. Axonal neuregulin-1 regulates myelin sheath thickness. Science 304, 700–703 (2004).

  3. 3.

    et al. Control of peripheral nerve myelination by the β-secretase BACE1. Science 314, 664–666 (2006).

  4. 4.

    et al. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J. 22, 2970–2980 (2008).

  5. 5.

    et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 9, 1520–1525 (2006).

  6. 6.

    , & The ADAMs family: coordinators of nervous system development, plasticity and repair. Prog. Neurobiol. 79, 73–94 (2006).

  7. 7.

    , , & Roles of Meltrin β/ADAM19 in the processing of neuregulin. J. Biol. Chem. 276, 9352–9358 (2001).

  8. 8.

    et al. Meltrin beta (ADAM19) mediates ectodomain shedding of Neuregulin beta1 in the Golgi apparatus: fluorescence correlation spectroscopic observation of the dynamics of ectodomain shedding in living cells. Genes Cells 12, 329–343 (2007).

  9. 9.

    , , , & Roles of meltrin-β/ADAM19 in progression of Schwann cell differentiation and myelination during sciatic nerve regeneration. J. Biol. Chem. 284, 2957–2966 (2009).

  10. 10.

    et al. Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice. BMC Neurosci. 6, 33 (2005).

  11. 11.

    et al. Adam22 is a major neuronal receptor for Lgi4-mediated Schwann cell signaling. J. Neurosci. 30, 3857–3864 (2010).

  12. 12.

    , , & The effects of alpha-secretase ADAM10 on the proteolysis of neuregulin-1. FEBS J. 276, 1568–1580 (2009).

  13. 13.

    , , , & Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins β1 and β2. Dev. Biol. 283, 459–471 (2005).

  14. 14.

    ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 6, 32–43 (2005).

  15. 15.

    et al. An essential role for ectodomain shedding in mammalian development. Science 282, 1281–1284 (1998).

  16. 16.

    , & The neurotrophin receptor p75NTR as a positive modulator of myelination. Science 298, 1245–1248 (2002).

  17. 17.

    et al. Notch controls embryonic Schwann cell differentiation, postnatal myelination and adult plasticity. Nat. Neurosci. 12, 839–847 (2009).

  18. 18.

    , , & Cleavage of p75 neurotrophin receptor by α-secretase and γ-secretase requires specific receptor domains. J. Biol. Chem. 280, 14563–14571 (2005).

  19. 19.

    et al. Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J. Biol. Chem. 284, 31018–31027 (2009).

  20. 20.

    et al. The disintegrin/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling. Development 138, 495–505 (2011).

  21. 21.

    et al. Cutting edge: TNF-α-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J. Immunol. 179, 2686–2689 (2007).

  22. 22.

    et al. Patterning of muscle acetylcholine receptor gene expression in the absence of motor innervation. Neuron 30, 399–410 (2001).

  23. 23.

    A relation between axone diameter and myelination determined by measurement of myelinated spinal root fibers. J. Comp. Neurol. 60, 437–471 (1934).

  24. 24.

    , , & Myelination determines the caliber of dorsal root ganglion neurons in culture. J. Neurosci. 5, 1563–1569 (1985).

  25. 25.

    & Axonal regulation of Schwann cell proliferation and survival and the initial events of myelination requires PI 3-kinase activity. J. Neurosci. 20, 4635–4645 (2000).

  26. 26.

    et al. Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J. Neurosci. 24, 6724–6732 (2004).

  27. 27.

    , & A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 23, 5080–5081 (1995).

  28. 28.

    et al. Conditional disruption of β1 integrin in Schwann cells impedes interactions with axons. J. Cell Biol. 156, 199–209 (2002).

  29. 29.

    et al. Isoform-specific expression and function of neuregulin. Development 124, 3575–3586 (1997).

  30. 30.

    et al. Nardilysin regulates axonal maturation and myelination in the central and peripheral nervous system. Nat. Neurosci. 12, 1506–1513 (2009).

  31. 31.

    , & Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem. J. 424, 79–88 (2009).

  32. 32.

    et al. Biochemical and kinetic characterization of BACE1: investigation into the putative species-specificity for β- and β′-cleavage sites by human and murine BACE1. J. Neurochem. 91, 1249–1259 (2004).

  33. 33.

    & Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615–29619 (2008).

  34. 34.

    , & Intracellular maturation and localization of the tumour necrosis factor α convertase (TACE). Biochem. J. 347, 131–138 (2000).

  35. 35.

    & Stimulation-induced down-regulation of tumor necrosis factor-α converting enzyme. J. Biol. Chem. 275, 14598–14607 (2000).

  36. 36.

    et al. The shedding activity of ADAM17 is sequestered in lipid rafts. Exp. Cell Res. 312, 3969–3980 (2006).

  37. 37.

    & Neuregulin-1 proteins in rat brain and transfected cells are localized to lipid rafts. J. Neurochem. 77, 1–12 (2001).

  38. 38.

    & Evidence that production and release of amyloid β-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386–17389 (1994).

  39. 39.

    , , , & Biosynthetic processing of neu differentiation factor. Glycosylation trafficking, and regulated cleavage from the cell surface. J. Biol. Chem. 270, 19188–19196 (1995).

  40. 40.

    , , , & Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357, 500–503 (1992).

  41. 41.

    & Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol. Cell. Biol. 29, 5679–5695 (2009).

  42. 42.

    et al. The myelin protein MAL affects peripheral nerve myelination: a new player influencing p75 neurotrophin receptor expression. Eur. J. Neurosci. 29, 2276–2290 (2009).

  43. 43.

    et al. The neurotrophin receptor p75NTR in Schwann cells is implicated in remyelination and motor recovery after peripheral nerve injury. Glia 55, 1199–1208 (2007).

  44. 44.

    et al. Sensory axon-derived neuregulin-1 is required for axoglial signaling and normal sensory function but not for long-term axon maintenance. J. Neurosci. 29, 7667–7678 (2009).

  45. 45.

    et al. Axonally derived neuregulin-1 is required for remyelination and regeneration after nerve injury in adulthood. J. Neurosci. 31, 3225–3233 (2011).

  46. 46.

    , & Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 4, 300–309 (2008).

  47. 47.

    et al. Nectin-like proteins mediate axon Schwann cell interactions along the internode and are essential for myelination. J. Cell Biol. 178, 861–874 (2007).

  48. 48.

    et al. β4 integrin and other Schwann cell markers in axonal neuropathy. Glia 17, 294–306 (1996).

  49. 49.

    , , & Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850–858 (1996).

  50. 50.

    et al. A minimal human MBP promoter-lacZ transgene is appropriately regulated in developing brain and after optic enucleation, but not in shiverer mutant mice. J. Neurobiol. 34, 10–26 (1998).

Download references

Acknowledgements

We thank S. Arber (University of Basel) for providing the HB9-cre transgenic line, M. Filbin (Hunter College) for antibodies, P. Podini for assistance with electron microscopy, G. Dina and A. Cattaneo for technical support and Y. Poitelon for artwork. This study was supported by the Federazione Italiana Sclerosi Multipla (FISM) (grant 2007/PC/01) and the Compagnia di San Paolo (C.T.); by the US National Institute of Health (grants R01-NS045630 (M.L.F.), R01-NS055256 (L.W.), R01-GM64750 (C.P.B.) and RO1-NS26001 (J.L.S.)); by Telethon Italia (grants GGP08021 (M.L.F.), GGP071100 (L.W.) and GPP10007 (C.T., L.W. and M.L.F.)). C.T. is a recipient of a FISM Transition Career Award.

Author information

Affiliations

  1. Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.

    • Rosa La Marca
    • , Federica Cerri
    • , Angelo Quattrini
    •  & Carla Taveggia
  2. Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.

    • Rosa La Marca
    • , Federica Cerri
    • , Angelo Quattrini
    •  & Carla Taveggia
  3. Department of Orthopedic Surgery, School of Medicine, Keio University, Tokyo, Japan.

    • Keisuke Horiuchi
  4. Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.

    • Angela Bachi
    • , M Laura Feltri
    •  & Lawrence Wrabetz
  5. Arthritis and Tissue Degeneration Program, Hospital for Special Surgery at Weill Medical College of Cornell University, New York, New York, USA.

    • Carl P Blobel
  6. Department of Cell Biology, New York University School of Medicine, New York, New York, USA.

    • James L Salzer
  7. Department of Neurology, New York University School of Medicine, New York, New York, USA.

    • James L Salzer
  8. Smilow Neuroscience Program, New York University School of Medicine, New York, New York, USA.

    • James L Salzer

Authors

  1. Search for Rosa La Marca in:

  2. Search for Federica Cerri in:

  3. Search for Keisuke Horiuchi in:

  4. Search for Angela Bachi in:

  5. Search for M Laura Feltri in:

  6. Search for Lawrence Wrabetz in:

  7. Search for Carl P Blobel in:

  8. Search for Angelo Quattrini in:

  9. Search for James L Salzer in:

  10. Search for Carla Taveggia in:

Contributions

R.L.M. conducted most of the experiments. F.C. and A.Q. performed morphological and ultrastructural analyses of sciatic nerves and ventral roots. K.H., C.P.B., M.L.F. and L.W. provided transgenic lines and helped with discussions. A.B. performed the mass spectrometry analyses. J.L.S. provided support and initially contributed to the experimental design. C.T. designed the experimental plan, supervised the project and wrote the paper. All authors commented on the paper.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Carla Taveggia.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–10 and Supplementary Table 1

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nn.2849